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Objective: To assess the safety profile of the low-dose levonorgestrel intrauterine system (LNG-IUS) total content 13.5 mg (average
approximate release rate 8 μg/24 h over the first year; LNG-IUS 8; Jaydess®) in adolescents.
Study design: In a Phase III study in 36 European centers, 304 healthy nulliparous or parous postmenarcheal adolescents (12–17 years) received
LNG-IUS 8 for 12 months. The primary outcome was the incidence of treatment-emergent adverse events (TEAEs). Secondary outcomes included:
serious TEAEs, adverse events of special interest, overall user satisfaction, discontinuation rate at 12 months, and Pearl Index.
Results: LNG-IUS 8 placement was successful in 303/304 participants (99.7%). Overall, 82.6% of participants reported TEAEs, and serious
TEAEs and serious study drug-related TEAEs were reported by 7.6% and 1.0% of participants, respectively. No cases of pelvic inflammatory
disease, ectopic pregnancy, or uterine perforation were reported. No pregnancies were reported during the 12-month study. AtMonth 12/study end,
the overall user satisfaction rate was 83.9%. Overall, 51 participants (16.8%) prematurely discontinued the study before 12 months; 13.8% of
participants discontinued owing to TEAEs.
Conclusions: No new or unexpected safety events were associated with the low-dose LNG-IUS 8. The safety profile of LNG-IUS 8 in
adolescents was consistent with that previously reported in adults. The high overall user-satisfaction rate at study end and the low
discontinuation rate over 12 months demonstrate that LNG-IUS 8 is a highly acceptable contraceptive method among adolescents.
Implications: This study is the first to assess the low-dose levonorgestrel intrauterine system LNG-IUS 8 (average approximate release rate
8 μg/24 h over the first year and total content 13.5 mg) specifically in femalesb18 years of age and confirms the safety and efficacy of LNG-
IUS 8 in an adolescent population.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Keywords: Contraception; Intrauterine contraception; LNG-IUS; Adolescent; Nulliparous1. Introduction
Despite a recent decline in adolescent pregnancy rates,
unintended pregnancy remains high in some regions and☆ Clinical Trial Registration Number: NCT01434160.
⁎ Corresponding author. Tel.: +46 8 517 72128; fax: +46 8 517 74314.
E-mail address: kristina.gemzell@ki.se (K. Gemzell-Danielsson).
http://dx.doi.org/10.1016/j.contraception.2016.02.004
0010-7824/© 2016 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/4.0/).countries across Europe and continues to be a serious public
health issue [1]. Worldwide, approximately 16 million females
aged 15–19 years and onemillion femalesb15 years give birth
every year [2]. The pregnancy rate reported in Europe in 2009
was 27.8 per 1000 adolescents aged 15–19; N150,000 legally
induced abortions and N200,000 births were recorded [1].
Unintended pregnancy rates among adolescents could be
substantially reduced through more widespread use of highlyess article under the CC BY-NC-ND license (http://creativecommons.org/
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Studies have shown that LARC is highly acceptable to
adolescents when included in contraceptive counseling.
Among 1099 participants aged 14–19 years who were
enrolled in the Contraceptive CHOICE study (in which
they were counseled on all contraceptives, and financial
barriers were removed), 69% chose LARC and, among
those, 43% chose the levonorgestrel intrauterine system
(LNG-IUS) [5]. Despite various guidelines advocating the
use of LARC in adolescents [4,6–8], the lack of data on
intrauterine contraception use in this population may prevent
more widespread utilization.
A smaller, low-dose LARC is available: LNG-IUS 8
(average approx. 8 μg/24 h over the first year; total content
13.5 mg; Jaydess®/Skyla® [Bayer HealthCare]). LNG-IUS 8
is placed with a narrower insertion tube (3.8 mm) than that
used for LNG-IUS 20 (4.4 mm) (Mirena® [Bayer HealthCare]).
This narrower insertion tube may be particularly suitable for use
in younger, nulliparous women. In a pivotal Phase III study
(NCT00528112), LNG-IUS 8 was shown to be highly
effective: the 3-year Pearl Index (PI) was 0.33 [9].
Additionally, LNG-IUS 8 was associated with a favorable
safety profile. However, that Phase III study excluded
participants agedb18 years. LNG-IUS 8 is expected to be as
effective in post-menarcheal adolescents as in adults and,
thus, may be an alternative to contraceptive methods that
rely on user compliance. We conducted this Phase III study
to explore the use of LNG-IUS 8 in an adolescent population
and obtain information on treatment-emergent adverse
events (TEAEs), satisfaction with use, and continuation.2. Materials and methods
This single-arm study (ClinicalTrials.gov: NCT01434160)
was conducted at 36 centers between September 2011 and
June 2013 in Austria, Belgium, Germany, Denmark,
Finland, Sweden, Norway, and The Netherlands under a
Pediatric Investigational Plan (PIP) (EMEA-000606-
PIP01-09) that fulfilled the conditions of Article 30 of
Regulation (EC) 1901/2006. The Plan was approved by the
European Medicines Agency's Paediatric Committee. Each
study site's independent ethics committee or institutional
review board reviewed and approved the protocol. The
study was conducted in accordance with the Declaration of
Helsinki and the International Conference on Harmonisation
guideline E6: GoodClinical Practice. All participants provided
written informed consent before study entry: because all
participants in this study wereb18 years of age at the time of
consent, some countries required additional consent from their
legal guardian(s).2.1. Inclusion and exclusion criteria
Healthy nulliparous or parous postmenarcheal adolescents
aged 12–17 years (inclusive), with regular menstrual cycles of21–35 days (without hormonal contraceptive use) requesting
contraception were recruited. Participants were required to
have a uterine sound depth of 6–10 cm, without conditions/
history that would contraindicate the use of an intrauterine
system, and a cervical smear not requiring further evaluation.
Participants were excluded if they were known or suspected to
be pregnant, were lactating, or had a vaginal delivery,
Cesarean section, or abortionb6 weeks before screening.
Further exclusion criteria were: a history of ectopic pregnancy;
distortion of the uterine cavity (e.g. due to fibroids) that was
likely (in the investigator's opinion) to cause problems with
placement, retention, or removal of LNG-IUS 8; any abnormal
uterine bleeding of unknown origin; acute or history of
recurrent pelvic inflammatory disease (PID); or any lower
genital tract infection (until successfully treated).
2.2. Study treatment
LNG-IUS 8 was assessed over 12 months. Participants
completing the 12-month study had the option to enter an
extension phase and continue use of LNG-IUS 8 for a further
2 years (up to 3 years of use in total, as indicated by the
product label) [10]. The extension phase will be published
separately. LNG-IUS 8 was placed within 7 days of menses
as per study protocol. For each participant, up to two
placement attempts were permitted; if the second attempt
was unsuccessful, the participant was withdrawn from the
study. The use of local anesthesia, oral analgesics, or dilation
was permitted at the investigator's discretion. Participants
were counseled to use condoms in addition to LNG-IUS 8 to
prevent sexually transmitted infections.
2.3. Study visits and assessments
Participants had a total of seven scheduled visits to the study
site: a screening visit, placement visit (baseline), and five visits
during treatment (at 1, 3, 6, 9, and 12 months after placement).
Vital signs were evaluated, and general physical and full
gynecological examinationswere performed at screening and at
the end of study (EOS) visit (Month 12, or at the EOS visit for
participants who discontinued prematurely). Pregnancy tests
were performed at screening, baseline, and at every study visit.
Adverse events (AEs), TEAEs, serious TEAEs, and AEs of
special interest (expulsion rates and incidences of uterine
perforation, ectopic pregnancy, PID, and ovarian cysts) were
assessed at every visit. Investigators assessed whether TEAEs
were related to the study drug on a case-by-case basis.
Investigators reported ovarian cysts as an AE if they were
considered to be non-physiologic and/or found to be N3 cm on
ultrasound, regardless of symptoms. Participants reported user
satisfaction at Month 12/EOS, using a 5-point Likert scale with
the options of “very satisfied”, “satisfied”, “neither satisfied nor
dissatisfied”, “dissatisfied”, and “very dissatisfied”. The overall
satisfaction rate was defined as the percentage of participants
who reported that they were “very satisfied” or “satisfied”.
Participants completed electronic vaginal bleeding diaries
daily; bleeding was recorded as “none”, “spotting” (no need
F1
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(need for sanitary protection but less than menstruation),
“normal”, or “heavy” (more than normal menstruation in the
participant's own experience). Participants assessed dys-
menorrhea at all visits; participants rated their experience of
dysmenorrhea in the 4 weeks prior to each visit as “none”,
“mild”, “moderate”, or “severe”. At baseline, investigators
assessed ease of placement as either “easy”, “slightly difficult”,
or “very difficult” and participants assessed pain on placement
as either “none”, “mild”, “moderate”, or “severe”, based on
their own perceptions of these terms.
2.4. Study outcomes
The primary outcome was the incidence of TEAEs over
12 months of LNG-IUS 8 use. Secondary outcomes included
AEs, serious TEAEs, and AEs of special interest; overall user
satisfaction; discontinuation rate at 12 months; PI; 28-day and
90-day bleeding profiles; dysmenorrhea; and ease and pain of
LNG-IUS 8 placement.
2.5. Statistical analyses
A sample size of 300 participants was determined to
provide a 95% chance of observing a particular AE at least
once during the study, if this AE occurred with a probability of
at least 1%. All analyses were based on the full analysis set (all
participants inwhom at least one placement attempt wasmade,
regardless of success). The overall discontinuation rate was
summarized usingKaplan–Meier analysis. The pregnancy rate
was expressed as the PI (number of pregnancies per 100
participant-years); 95% confidence interval (CI) calculations
assumed that the number of pregnancies followed a Poisson
distribution. The cumulative failure rate was summarized
using Kaplan–Meier analysis. Times during which partici-
pants used concomitant contraception were subtracted from
exposure times used for the unadjusted PI and Kaplan–MeierEnrolled
(N=343)
Full analysis seta
(N=304)
(includes one participant
with unsuccessful placement)
Completed 12-month studyb
(N=253)
E
Entered optional 
extension study
(N=220)
•
•
•
•
•
•
Fig. 1. Disposition of participants. aThe full analysis set included all participants for wh
in this paper are for the 12-month study only. cThis death was the result of a motor v
LNG-IUS, levonorgestrel intrauterine system; LNG-IUS 8, LNG-IUS total content 13cumulative failure rate calculations. Bleeding profiles (mean
number of bleeding and spotting days) over 12 months were
analyzed using 28-day and 90-day reference intervals (RIs),
and bleeding patterns according to the World Health
Organization criteria [11] were analyzed using 90-day RIs.3. Results
3.1. Study participants
Of the 343 participants screened for inclusion, 304 were
assigned to treatment and included in the full analysis set
(Fig. 1). Overall, 303/304 participants had a successful
placement. Baseline characteristics, including contraceptive
methods at screening, are summarized in Table 1.
3.2. Safety
Over 12 months of treatment, 259 participants (85.2%)
reported AEs. TEAEs were reported by 251 participants
(82.6%; primary outcome) and are summarized in Table 2; the
most frequently reported and study drug-related TEAEs are
summarized in Table 3. Three participants (1.0%) reported
study drug-related serious TEAEs: pelvic pain by two (0.7%)
and endometritis by one (0.3%). The case of endometritis did
not fulfill the criteria for PID as defined in the study protocol.
No cases of PID, ectopic pregnancy, or uterine perforation
were reported. LNG-IUS 8 expulsion occurred in 10
participants (3.3%); of these expulsions, nine were partial
and one was complete.
3.3. User satisfaction
The overall satisfaction rate at Month 12/EOS was 83.9%
(95% CI: 79.3–87.8). Overall, 53.6%, 30.3%, 5.6%, 6.3%, and
1.0% of participants were “very satisfied", “satisfied", “neither
satisfied nor dissatisfied", “dissatisfied", and “very dissatisfied",
respectively. Data were missing for 3.3% of participants.xcluded at screening (n=39; 11.4%) 
• Screening failures (n=26) 
• Withdrew consent (n=5) 
• Lost to follow-up (n=4) 
• Due to AEs (n=2)  
• Other (n=2) 
Discontinued 12-month study 
(n=51; 16.8%)
AEs (n=40)
Other (n=4)
Lost to follow-up (n=3)
Protocol violation (n=2)
Placement failure (n=1)
Death (n=1)C
om at least one attempt at LNG-IUS 8 placement was made. bThe data presented
ehicle accident and was not considered study drug-related. AE, adverse event;
.5 mg (average approximate release rate 8 μg/24 h).
Table 1
Baseline characteristics (full analysis set)
Variable LNG-IUS 8 (N=304)
Mean age, years (range) 16.2 (12–18a)
Mean weight, kg (range) 61.4 (41.7–115.0)
Mean BMI, kg/m2 (range) 22.1 (16.4–43.3)
Nulliparous, n (%) 297 (97.7)
Never had an abortion, n (%) 286 (94.1)
Mean uterus sound depth, cm (S.D.) 6.7 (0.61)
Regular menstrual cycles, n (%) 303 (99.7)
Mean cycle length, days (S.D.) 28.3 (2.6)
Menstrual bleeding, %
Normal bleeding 64.1
Heavy bleeding 27.3
Intracyclic bleeding 3.3
Contraceptive method at screening, n (%)
Oral contraceptive 157 (51.6)
Barrier method 69 (22.7)
Vaginal hormonal contraception 4 (1.3)
IUS 3 (1.0)
Implant 1 (0.3)
Transdermal hormonal contraception 1 (0.3)
None 69 (22.7)
BMI, body mass index; IUS, intrauterine system; LNG-IUS, levonorgestrel
intrauterine system; LNG-IUS 8, LNG-IUS total content 13.5 mg (average
approximate release rate 8 μg/24 h); S.D., standard deviation.
a One participant had LNG-IUS 8 placed on her 18th birthday.
able 3
ost frequently reported TEAEs (reported by ≥3% of participants) and
tudy drug-related TEAEs
utcome
LNG-IUS 8 (N=304), n (%)
Most frequently
reported TEAEs
Study drug-related
TEAEs
ysmenorrhea⁎ 68 (22.4) 37 (12.2)
elvic pain⁎ 59 (19.4) 45 (14.8)
asopharyngitis 41 (13.5) 0
rocedural pain⁎ 39 (12.8) 21 (6.9)
eadache 34 (11.2) 4 (1.3)
cne 26 (8.6) 20 (6.6)
bdominal pain 22 (7.2) 0
ystitis 20 (6.6) 0
varian cyst 18 (5.9) 13 (4.3)
fluenza 18 (5.9) 0
aginal infection 14 (4.6) 0
rinary tract infection 12 (3.9) 1 (0.3)
ausea 12 (3.9) 1 (0.3)
astroenteritis 11 (3.6) 0
evice expulsion 10 (3.3) 10 (3.3)
aginal hemorrhage⁎ 9 (3.0) 8 (2.6)
inusitis 9 (3.0) 0
NG-IUS, levonorgestrel intrauterine system; LNG-IUS 8, LNG-IUS
tal content 13.5 mg (average approximate release rate 8 μg/24 h);
EAE, treatment-emergent adverse event.
⁎ Adverse event data are presented according to investigator's causal
ssessment on a case-by-case basis, which accounts for the differences between
e most frequently reported TEAEs and study drug-related TEAEs.
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Overall, 51 participants (16.8%) prematurely discontinued
the study before 12 months. The most common study
drug-related TEAEs leading to discontinuation were pelvic
pain (n=11; 3.6%), device expulsion (n=10; 3.3%), acne
(n=5; 1.6%), and dysmenorrhea (n=5; 1.6%).
3.5. Contraceptive efficacy
No pregnancies were reported during the 12-month study.
The 12-month unadjusted PI was 0.00 (95% CI: 0.00–1.86),
and the Kaplan–Meier 12-month cumulative failure rate was
0%. Exposure relevant for the unadjusted PI calculation
(198.76 participant-years) was approximately 72% of theTable 2
Summary of number of participants with TEAEs
Outcome
LNG-IUS 8 (N=304),
n (%)
Any TEAE
Study drug-related TEAEs
Study procedure-related TEAEs
251 (82.6)
127 (41.8)
63 (20.7)
Any serious TEAE
Study drug-related serious TEAEs
Study procedure-related serious TEAEs
23 (7.6)
3 (1.0)
0
TEAEs leading to discontinuation
Drug-related TEAEs leading to discontinuation
42 (13.8)
38 (12.5)
Serious TEAEs leading to discontinuation 2 (0.7)
LNG-IUS, levonorgestrel intrauterine system; LNG-IUS 8, LNG-IUS
total content 13.5 mg (average approximate release rate 8 μg/24 h);
TEAE, treatment-emergent adverse event.T
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thtotal exposure, owing to the allowance of concomitant
condom use.
3.6. Bleeding profiles
The number of participants contributing 28-day RI data
fell from 141 participants at RI 1 to 36 participants in RI 13,
which was as a result of a technical issue and a lack of
compliance with eDiary completion. The extent of missing
data precluded a meaningful analysis of bleeding.
3.7. Dysmenorrhea
The number of participants experiencing dysmenorrhea
during LNG-IUS 8 use decreased over time from 189/304
(62.2%) in the 4 weeks prior to baseline to 114/298 (38.3%)
in the 4 weeks prior to Month 12/EOS. Moderate or severe
dysmenorrhea was reported by 38.2% of participants at
baseline, 20.0% at Month 1, 13.1% at Month 3, 15.7% at
Month 6, 16.4% at Month 9, and 18.5% at Month 12/EOS.
3.8. Ease and pain of LNG-IUS 8 placement
Overall, 310 placements were attempted in 304 partici-
pants, and placement was successful in 303/304 participants
(99.7%). For participants who had a successful placement,
most investigators rated the procedure as “easy” (94.4% of
cases). A further 4.6% and 1.0% of investigators rated the
procedure as “slightly difficult" and “very difficult",
respectively. Pain on LNG-IUS 8 placement was reported
by 20.5%, 34.3%, 34.3%, and 10.9% of participants as
511K. Gemzell-Danielsson et al. / Contraception 93 (2016) 507–512“none", “mild", “moderate", and "severe", respectively.
Dilation was performed in 29.3% of participants, and local
anesthesia was administered paracervically/intracervically in
31.9% of participants. Thirteen (4.3%) participants were
administered misoprostol as a cervical softener.4. DiscussionDespite a recent decline in adolescent pregnancy rates,
unintended pregnancy continues to be a serious public health
issue [1]. Adolescent pregnancy could be substantially
reduced through more widespread use of contraceptive
methods that do not require user compliance, such as LARC
methods, particularly LNG-IUS 8.
LNG-IUS 8was not associatedwith any new or unexpected
safety events, and the safety profile of LNG-IUS 8 observed
in this study of adolescents aged 12–17 years is consistent
with that observed in nulliparous and parous adults (aged
18–35 years) evaluated in a pivotal Phase III study [9].
Ovarian cysts were reported in 18 participants (5.9%);
however, because ovarian cysts were reported by the
investigator as an AE if they were felt to be non-physiologic
and/or were found to be N3 cm on ultrasound, they may
have been reported as an AE even if they were asymptomatic,
thus potentially overstating their clinical relevance. In
comparison, in the pivotal Phase III study, ovarian cysts
were reported as an AE in 10% of participants during the first
12 months of use.However, some of theseAEsmay have been
reported when there was an ultrasound finding of a cystic
structure≤3 cm if theywere associatedwith symptoms, or if a
cyst had a non-functional appearance [12].
LNG-IUS 8 was associated with a high overall user-
satisfaction rate (83.9% at 12 months/EOS), similar to that
observed in adults (95% at the end of 3 years) [9]. Our findings
also correlate with those observed in the Contraceptive
CHOICE study: of 330 women using LNG-IUS and 55
women using a copper intrauterine device aged 14–19 years,
77.2% and 72.0% of participants, respectively, reported that
they were either “very satisfied” or “somewhat satisfied”
with their intrauterine contraception at 12 months [5]. In our
study, findings regarding high user satisfaction are rein-
forced by the low premature discontinuation rate (16.8% at
12 months). Evidence shows that discontinuation rates are
typically lower with LARC compared with short-acting
reversible contraception; for example, in the Contraceptive
CHOICE study, the 12-month discontinuation rates among
N1000 participants aged 14–19 years were 19.0% for LARC
(19.4% for LNG-IUS) and 56.0% for short-acting reversible
contraception [5].
No pregnancies were reported during the study; however,
relevant exposure, which contributed to the PI calculation,
was low (72%) because participants were counseled to
use condoms to prevent sexually transmitted infections. The
current study was not powered to assess the contraceptiveefficacy of LNG-IUS 8, which has been established previously
(3-year PI: 0.33) [9].
Poor compliance with bleeding diaries makes bleeding
data unreliable; consequently, we are unable to draw any
meaningful conclusions.
Overall, investigators rated 94.4%ofLNG-IUS8 placements
in participants (97.7%ofwhomwere nulliparous) as “easy”, and
89.1% of participants rated placement pain as no more than
“moderate”. By comparison, in a pivotal Phase III study
conducted in parous and nulliparous women, investigators rated
placement of LNG-IUS 8/LNG-IUS 13 (LNG-IUS total content
19.5 mg [average approximate release rate 13 μg/24 h over the
first year]) –which were the same size and placed with identical
insertion tubes – as “easy” in 89.6% of women overall and in
84.2% of nulliparous women [13]. Placement-related pain was
rated as no more than “moderate” by 92.4% of women overall
[9] and by 84.5% of nulliparous women [13]. However,
although in both studies LNG-IUS8was placedwith a 3.80 mm
outer diameter inserter, a new inserter with fewer preparatory
steps was used in this study, which may have impacted on
investigators' assessment of placement. Furthermore, in both
studies, ease of placement and placement-related pain assess-
ments were not based on an objective scale but were solely
based on investigators' and participants' perceptions, respec-
tively, of what these terms mean.
Most placements were performed without dilation or
administration of local anesthesia. When dilation was
performed or pain medication (local anesthesia or analgesics)
was given, this was done prophylactically (to facilitate
intrauterine system placement) rather than in response to
difficulty or pain encountered during LNG-IUS 8 placement.
This study – the first to assess the next-generation, low-dose
LNG-IUS 8 in femalesb18 years old – confirms the safety,
efficacy, and acceptability of LNG-IUS 8 in an adolescent
population and provides data that could be considered during
contraceptive counseling. LNG-IUS 8 offers another contra-
ceptive option for young women and may improve the uptake
of LARC in this group, which, in turn, has the potential to
change clinical practice.Acknowledgements
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